Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 2, 2010, Pages 162.e1-162.e8

  Cross, Sarah N ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   Anagnostou, Valsamo K ^a   Brower, Stacey L ^b   Richter, Christine E ^a   Siegel, Eric R ^c   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Precision Therapeutics Inc   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

chemoresistance; chemosensitivity; endometrial neoplasms; HER 2 neu; uterine serous tumors

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE SEROUS PAPILLARY ADENOCARCINOMA;

EID: 77955661117     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.02.056     Document Type: Article

References (25)

1. M. Thun, J. Xu, Y. Hao, E. Ward, R. Siegel, and A. Jemal Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10
3. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
4. C. Levenback, T.W. Burke, E. Silva, et al. Uterine papillary serous carcinoma (USPC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC) Gynecol Oncol 46 1992 317 321
5. L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: pattern of spread and treatment Clin Obstet Gynecol 39 1996 686 695
6. P.E. Schwartz The management of serous papillary uterine cancer Curr Opin Oncol 18 2006 494 499
7. A.D. Santin, S. Bellone, S. Van Stedum, et al. Determination of HER-2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecol Oncol 98 2005 24 30
8. A.D. Santin, S. Bellone, S. Van Stedum, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma Cancer 104 2005 1391 1397
9. A.D. Santin, E.R. Siegel, S. Bellone, et al. Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer Am J Obstet Gynecol 192 2005 813 818
10. T.P. Diaz-Montes, H. Ji, A.E. Smith Sehdev, et al. Clinical significance of HER-2/neu overexpression in uterine serous carcinoma Gynecol Oncol 100 2006 139 144
11. T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstrale, O.I. Olopade, and G.F. Fleming An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 108 2008 3 9
12. C. Wright, B. Angus, S. Nicholson, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res 49 1989 2087 2090
13. A. Berchuck, A. Kamel, R. Whitaker, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 1990 4087 4091
14. D.J. Hetzel, T.O. Wilson, G.L. Keeney, P.C. Roche, S.S. Cha, and K.C. Podratz HER-2/neu expression: a major prognostic factor in endometrial cancer Gynecol Oncol 47 1992 179 185
15. K. El-Sahwi, S. Bellone, E. Cocco, et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma Br J Cancer 102 2010 134 143
16. S.L. Brower, J.E. Fensterer, and J.E. Bush The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy G. Mor, A.F. Alvero, eds. Methods in molecular biology; apoptosis and cancer: methods and protocols 2008 Humana Press Totowa, NJ 57 78
17. H. Gallion, W.A. Christopherson, R.L. Coleman, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay Int J Gynecol Cancer 16 2006 194 201
18. Y. Yarden, and M.X. Sliwkowski Untangling the erbB signaling network Nat Rev Mol Cell Biol 2 2001 127 137
19. B.M. Slomovitz, R.R. Broaddus, and T.W. Burke HER-2/neu overexpression and amplification in uterine papillary serous carcinoma J Clin Oncol 22 2004 2136
20. C. Morrison, V. Zanagnolo, N. Ramirez, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients J Clin Oncol 24 2006 2376 2385
21. C.M. Tsai, K.T. Chang, R.P. Perng, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations J Natl Cancer Inst 85 1993 897 901
22. C.M. Tsai, D. Yu, K.T. Chang, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells J Natl Cancer Inst 87 1995 682 684
23. Y. Hasegawa, M. Goto, N. Hanai, et al. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma Oncology 73 2007 104 111
24. M.S. Orr, P.M. O'Connor, and K.W. Kohn Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells J Natl Cancer Inst 92 2000 987 994
25. M.D. Pegram, R.S. Finn, K. Arzoo, M. Beryt, R.J. Pietras, and D.J. Slamon The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 1997 537 547